Page last updated: 2024-12-05

2,6-dichloro-4-nitrophenol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID12066
SCHEMBL ID887770
MeSH IDM0065331

Synonyms (31)

Synonym
nsc 4123
einecs 210-563-6
ai3-03649
nsc4123
618-80-4
2,6-dichloro-4-nitrophenol
phenol,6-dichloro-4-nitro-
nsc-4123
4-nitro-2,6-dichlorophenol
SGCUT00106
2-6-dichloro-4-nitrophenol
inchi=1/c6h3cl2no3/c7-4-1-3(9(11)12)2-5(8)6(4)10/h1-2,10
TO_000007
2,6-dichloro-4-nitrophenol, 98%
phenol, 2,6-dichloro-4-nitro-
AC-10708
D0389
AKOS000120855
FT-0610585
AE-641/02443039
SCHEMBL887770
2,6-dichloro-4-nitro-phenol
DTXSID6060686
2,6-dichloro4-nitrophenol
mfcd00014715
F0001-1644
AS-10936
D89642
EN300-20887
CS-W015247
36WLM45T7L

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" At lower concentrations, P and PS had no toxic actions until 72h."( Pregnenolone protects the PC-12 cell line against amyloid beta peptide toxicity but its sulfate ester does not.
Akan, P; Fadiloglu, M; Genc, S; Kizildag, S; Oktem, MA; Ormen, M, 2009
)
0.35

Dosage Studied

ExcerptRelevanceReference
" DNA adducts from hepatocytes dosed with N-hydroxy-PhIP, however, resulted in a decrease in adduct levels from cells pretreated with PCP or DCNP."( The role of sulfation and/or acetylation in the metabolism of the cooked-food mutagen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine in Salmonella typhimurium and isolated rat hepatocytes.
Buonarati, MH; Felton, JS; Malfatti, MA; Shen, NH; Turteltaub, KW,
)
0.13
" Two weeks treatment of E2011 alone at an oral dosage of 150 mg/kg induced hepatocellular changes characterized by nuclear enlargement."( Protection from drug-induced hepatocellular changes by pretreatment with conjugating enzyme inhibitors in rats.
Aoki, T; Hosokawa, S; Sagami, F; Sato, G; Tsukidate, K, 2001
)
0.31
"To develop an injectable dosage form of the daily oral HIV drugs, tenofovir (T), lamivudine (L), and dolutegravir (D), creating a single, complete, all-in-one TLD 3-drug-combination that demonstrates long-acting pharmacokinetics."( A novel formulation enabled transformation of 3-HIV drugs tenofovir-lamivudine-dolutegravir from short-acting to long-acting all-in-one injectable.
Collier, AC; Delle Fratte, R; Eguchi, M; Ho, RJY; Melvin, AJ; Perazzolo, S; Stephen, ZR; Xu, X, 2023
)
0.91
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (82)

TimeframeStudies, This Drug (%)All Drugs %
pre-199033 (40.24)18.7374
1990's26 (31.71)18.2507
2000's10 (12.20)29.6817
2010's6 (7.32)24.3611
2020's7 (8.54)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 19.51

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index19.51 (24.57)
Research Supply Index4.49 (2.92)
Research Growth Index4.70 (4.65)
Search Engine Demand Index18.60 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (19.51)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (2.27%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other86 (97.73%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]